clinical trial · NCT05344508

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

$INSM →·—·approved for marketing

Non-Cystic Fibrosis BronchiectasisBrensocatib

brief summary

The purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.

started

—

primary completion

—

completion

—

last updated

Nov 4, 2025

detailed description

Participants will receive brensocatib 10 mg, oral tablets, once daily.

official title

Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol